Rangeley Capital’s LAVA Therapeutics LVTX Stock Holding History

Rangeley Capital’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-165,000	Closed	-$257K	–	143
2025 Q3	$257K	Buy	165,000 +137,927	+509%	+$206K	0.22%	81
2025 Q2	$35.7K	Buy	+27,073	New	+$34.5K	0.04%	65

Rangeley Capital's LVTX Position: Q4 2025 in Review

Rangeley Capital sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 165,000 shares — an estimated $257K sold.

Rangeley Capital first reported a position in LVTX in Q2 2025 and held it in 2 quarters. The position peaked at $257K in Q3 2025. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.

Rangeley Capital reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
Rangeley Capital sold 165,000 LAVA Therapeutics shares in Q4 2025, an estimated $257K.
Rangeley Capital first reported a position in LAVA Therapeutics in Q2 2025 and held it in 2 quarters.
Rangeley Capital's LAVA Therapeutics position peaked at $257K in Q3 2025.
0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.

Based on Rangeley Capital's 13F filing for Q4 2025, filed 17 Feb 2026.